Company Overview and News
KUALA LUMPUR: JF Apex Research expects Ikhmas Jaya Group Bhd, Symphony Life Bhd , UCrest Bhd, Kumpulan Perangsang Selangor Bhd (KPS) and Gamuda Bhd to generate trading interest following their latest corporate news.
KUALA LUMPUR: Century Bond Bhd (CBB), a subsidiary of Kumpulan Perangsang Selangor Bhd (KPS), has entered into a joint-venture (JV) agreement with China-based Honda Printing Holdings Ltd (Honda Printing) to produce offset carton boxes for the manufacturing sector.
Debt which will not be paid back for 100 years is being raised by Wellcome Trust, the multi-billion investor which funds medical research and charities.
Austria issued €3.5 billion of a new 100-year bond, the biggest syndication of a century bond in Europe to date. Janus Henderson’s Mitul Patel, Head of Interest Rates, shares his views on the positive aspects of such ultra-long bonds.
• Raise Wages, Kill Jobs? Seven Decades of Historical Data Find No Correlation Between Minimum Wage Increases and Employment Levels (NELP) • The 100 Year: A Take on the Century Bond (GMO) see also Chance for Smart U.S. Debt Funding Is Slipping Away (Bloomberg View) • What We Said When the World Changed (Collaborative Fund) • How Jeff Sessions wants to bring back the war on drugs (Washington Post) • Google’s war on fake news goes global: Search results now tagged ‘true’ or ‘false’ (ZDNet) see also Gaming Google for Profit and Ideology (BloombergView)
KUMPULAN Perangsang Selangor Bhd (KPS), which is 57.88% owned by the Selangor investment arm Kumpulan Darul Ehsan Bhd, is focusing on its international expansion following the completion of acquisitions that took place last year.
MarketWrap: Wall Street surged on Wednesday, with the Dow industrials and S&P 500 hitting fresh records, as equities continued their march upward after the presidential election of Donald Trump and a new high for transportation stocks added to the bullish tone. - Reuters The DJIA rose 297.84 points, or 1.55%, to 19,549.62, the S&P 500 gained 29.12 points, or 1.32%, to 2,241.35 and the Nasdaq added 60.
KUALA LUMPUR (Dec 6): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Dec 7) could include: Berjaya Food Bhd (BFood), Sarawak Oil Palms Bhd (SOPB), MKH Bhd, Omesti Bhd, Asia Media Group Bhd, Stone Master Corp Bhd and Kumpulan Perangsang Selangor Bhd (KPS).
MarketWrap: Wall Street ended barely changed on Monday as investors digested the latest large-scale corporate mergers as well as the most recent twist in a tumultuous US presidential election. - Reuters The DJIA fell 18.77 points, or 0.1%, to 18,142.42, the S&P 500 lost 0.26 points, or 0.01%, to 2,126.15 and the Nasdaq dropped 0.97 points, or 0.02%, to 5,189.14. Forex summary *The ringgit gained 0.
KUALA LUMPUR (Oct 31): Based on corporate announcements and news flow today, companies that may be focus tomorrow (Nov 1) could include: AirAsia, AirAsia X, MAHB, Coastal Contracts, Kumpulan Perangsang Selangor, Ekovest, Sasbadi and Caring.
MarketWrap: All three major US stock indexes closed at record highs on Thursday for the first time since 1999 as surging oil prices and strong earnings from department stores Macy's and Kohl's buoyed investor sentiment. - Reuters The DJIA climbed 0.64% to end at 18,613.52, the S&P 500 gained 0.47% to 2,185.79 and the Nasdaq added 0.46% to 5,228.40. Forex summary *The ringgit lost 0.05% to 4.0065 per US$ *It was 0.
KUALA LUMPUR (Aug 12): It was a morning of contrating fortunes for Kumpulan Perangsang Selangor Bhd (KPS) and Century Bond Bhd (CenBond) after the former said it planned to take CenBond private for RM209 million or RM1.75 per share.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...